The Tangled Story Of Why Ebola Vaccine Research Came Up Short
Posted on AllSides October 18th, 2014
From The Left
Around 2008, an Ebola outbreak in Africa sparked a renewed push within the U.S. biomedical research community to find a vaccine. A company called Integrated BioTherapeutics Inc. was given a $5.8 million contract from the National Institutes of Health for vaccine research.
Integrated Biotherapeutics, with subcontractor Protein Sciences Corp., began exploring a way to develop proteins associated with Ebola as a means of boosting antibodies. They hoped to introduce benign elements of the virus to the immune system, priming the body to more quickly recognize and attack the disease in...